What Is Myelofibrosis?

It is a life-threatening bone marrow disorder which disturbs the normal growth of blood cells in a body. Such tends to consequent scarring in the bone marrow, causing weakness, anemia and enlarged liver and spleen. The disorder is a rare form of chronic leukemia, and belongs to a diseases group named myeloproliferative disorders. Typically, the condition of individuals suffering from myelofibrosis gradually worsens, where few ultimately develops a more acute type of leukemia.

One may have myelofibrosis for years without any prominent symptoms. Its treatment aims to ease the symptoms.

What Are The Symptoms Of Myelofibrosis?

Usually, the disorder advances gradually. In its initial stages, many individuals do not notice any signs, however as it increasingly interferes with the normal production of blood cells with the passage of time, symptoms begins more and more apparent, they may include:

What Causes Myelofibrosis?

Developing genetic mutation in the stem cells of blood causes myelofibrosis. Normally, these stem cells replicate and split into many specialized cells which compose our blood-platelets, white blood cells and red blood cells. What exactly grounds genetic mutation, is still a mystery.

What Are The Risk Factors Of Myelofibrosis?

Even though, what exactly triggers the bone marrow disorder is unknown till date, however few factors are considered to increase its chances:

What Are The Potential Complications Of Myelofibrosis?

Certain complications linked with myelofibrosis include:

How Is Myelofibrosis Diagnosed?

In order to diagnose myelofibrosis, the doctor can suggest the following procedures and tests:

How Is Myelofibrosis Treated?

An identified curative treatment of myelofibrosis is allogeneic stem cell transplantation, though; the treatment tends to involve potential risks. Few other treatment options of the bone marrow disorder are highly supportive and include:

Few other treatment options such as hydroxyurea, alpha-interferon and dexamethasone also play a major role for treating the bone marrow disoder.

Thalidomide and lenalidomide are also used for treating myelofibrosis, however they share a common side-effect, peripheral neuropathy. Frequent blood transfusion is often needed by the patient of myelofibrosis. Lastly, ruxolitinib, is another latest treatment option approved for myelofibrosis.

 

By : Natural Health News

Leave a Reply

Your email address will not be published. Required fields are marked *